protodigmlabs (@protodigmlabs) header
protodigmlabs (@protodigmlabs) profile picture

Protodigm: options x evidence | Sister company to @ideapharma | Contract skunkworks/ next-gen CRO | Pointing AI at the right question

Joined January 2021
Photo by protodigmlabs (@protodigmlabs)Photo by protodigmlabs (@protodigmlabs)Photo by protodigmlabs (@protodigmlabs)Photo by protodigmlabs (@protodigmlabs)Photo by protodigmlabs (@protodigmlabs)Photo by protodigmlabs (@protodigmlabs)Photo by protodigmlabs (@protodigmlabs)
protodigmlabs retweeted
Here’s that chart… Blockbuster drugs (drugs that sold over $1bn in 2022): their 2022 revenue split by year of first approval… @PeterKolchinsky was almost right 😅
4
6
1
23
23,035
protodigmlabs retweeted
“Phase I/ II is the period when you really should be looking to find out not just that your drug isn’t terrible, but that it might be great. This is the time to try your best to kill it.” Enemies of pharmaceutical innovation ideapharma.substack.com/p/en…
1
2
647
protodigmlabs retweeted
Alex is right, *but* look at the absolute horror of this… As I wrote yesterday, making pI/pII easier is the wrong behaviour, but it’s what has happened, with the result you’d expect… linkedin.com/newsletters/asy… (Plus, they define ‘productivity’ incorrectly) – at East, England
1
4
10
4,201
protodigmlabs retweeted
Great conversation with Mike Rea about the key drivers of organizational performance and growth.
“Leaders create the culture that drives the behavior that produces results.” How pharma can create elite teams… Fantastic, hugely enjoyable episode of the podcast with @TimothyKight youtu.be/DZfReX3kDH8
5
23
protodigmlabs retweeted
For my Boston/ Cambridge friends, I’ve read Brian’s excellent book, and it really is a great addition to the @PeterKolchinsky, @John_LaMattina shelf. Treats the subject with the complexity it deserves. I’m sure you will like this meeting on the 1st – at East, England
protodigmlabs retweeted
This feels like the key diagram in here… positioningpharmaceuticals.s… #immunooncology #SITC2022 cc @MyOncology @paulpetertak – at East, England
This new article analyzes racial and ethnic diversity in immuno-oncology clinical trials and the potential strategies to reduce barriers to more diverse trials go.nature.com/3A4eM0J
3
4
protodigmlabs retweeted
“Whenever ‘move fast and break things’ comes up, lots of pharma folks will add ‘in pharma we can’t break things…’ Pharma breaks things all the time. 99 of 100 things, to be exact. It ‘breaks’ most of the molecules it puts into its pipeline, but slowly” ideapharma.substack.com/p/mi… – at East, England
1
7
protodigmlabs retweeted
Number of people in pharma who believe the same molecule in 2 different companies ends up in the same place: 0 No of companies leaning into the ‘why’…: some, and growing… “First Among Equals” ideapharma.substack.com/p/fi… – at East, England
1
6
Mike Rea, CEO of @ideapharma and @protodigmlabs made our 2022 Power List, thanks to your nominations! Nominations for The Medicine Maker Power List 2023 are now open - this is your chance to help curate the great minds of the #pharma industry. https://nitter.cf/t.co/10UiCynj3F
3
5
protodigmlabs retweeted
UK/London friends of #CNSSummit and @ideapharma, join us this Thursday, July 28th for a fantastic meetup filled with drinks, food, and great company! This meetup is free for attendees, register here: eventbrite.com/e/cns-summit-…
This… And dumb follow-the-herd path-to-market strategy so companies are always headed into SF in JPM week type costs
This is really what is driving up the cost of drug development. The MASSIVE price gouging of biotech contractors, landlords, CROs, etc. Lot of people making a ton of money while contributing no innovation. The biotech sector is prime for innovation outside of drug development.
protodigmlabs retweeted
Had a conversation (with a pharmaco) about companies looking for ‘white space’ in future markets… Drew this… There is SO much more than McK/ BCG-type processes will ever understand
1
2
10
protodigmlabs retweeted
If you went into someone’s office and they were quietly reading a book, what would you think? – at East, England
26%They’re not working
43%They’re researching
31%They’re self-improving
90 votes • Final results
5
1
3
protodigmlabs retweeted
What is difference btwn ur drug molecule in phase 1 & the same molecule on the market? It’s a trick question: there is no difference. The only difference between A & B is the decisions that you make and the evid that u choose to collect positioningpharmaceuticals.s… via @ideapharma
2
6
protodigmlabs retweeted
“The reason DTC ads suck so much is not (just) the lack of imagination or understanding of positioning in agencies and Commercial. The reason DTC ads suck so much is the lack of imagination and understanding of positioning in R&D.” linkedin.com/pulse/whos-writ… – at Beverly Hills, CA
1
1
5
protodigmlabs retweeted
“Key to this asymmetry, to the ability to execute, at companies like Pfizer and AstraZeneca, were a kind of agility based not just on thinking, but knowing they could *do*…” linkedin.com/pulse/decision-… Decision-making asymmetry that matters to all of us
2
2
10
‘Follow the science’ but not ‘follow the decision science’…
1
protodigmlabs retweeted
At some point, you’re going to want someone to want to write a prescription for your drug, someone to want to pay for it, someone to want to take it, and someone to let them. positioningpharmaceuticals.s… via @ideapharma
1
4
1
10
protodigmlabs retweeted
A reminder: Lipitor itself was bigger than Pfizer before it bought Lipitor… “In the year after it was ‘discovered’, Pfizer (+ BioNTech’s) vaccine nearly doubled the giant’s revenues, with 45% of its $81.3bn in ’21 fueled by the vaccine…” fortune.com/2022/04/20/top-p… @the_sy_guy
1
2
protodigmlabs retweeted
Some good ‘side effects’ from crunching hundreds of metrics in the 2022 Pharmaceutical Innovation and Invention Index… This and more in the white paper… ideapharma.com/pii/
1
5
2
13